SCIVANTA MEDICAL CORP: 10-Q filed 2015-06-12

Name: SCIVANTA MEDICAL CORP: 10-Q filed 2015-06-12
Creator: SCIVANTA MEDICAL CORP

What SCIVANTA MEDICAL CORP reported in its quarterly report filed 2015-06-12 (fiscal Q2 2015): 17 published measures, 43 facts as tagged in accession 0001213900-15-004427.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-06-12
Fiscal period: fiscal Q2 2015
Accession: 0001213900-15-004427 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SCIVANTA MEDICAL CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-04-30	32,163	USD
At 2014-10-31	32,787	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-04-30	1,240,701	USD
At 2014-10-31	1,097,359	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-04-30	-1,208,538	USD
At 2014-10-31	-1,064,572	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-04-30	26,809	USD
At 2014-10-31	26,114	USD
At 2014-04-30	78,829	USD
At 2013-10-31	19,908	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-02-01 to 2015-04-30	-77,768	USD	89
2014-11-01 to 2015-04-30	-151,576	USD	181
2014-02-01 to 2014-04-30	-135,526	USD	89
2013-11-01 to 2014-04-30	-197,746	USD	181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-11-01 to 2015-04-30	-49,305	USD	181
2013-11-01 to 2014-04-30	-161,464	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2014-11-01 to 2015-04-30	50,000	USD	181
2013-11-01 to 2014-04-30	220,385	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-04-30	-24,293,096	USD
At 2014-10-31	-24,141,520	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-11-01 to 2014-04-30	32,333	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-02-01 to 2015-04-30	-59,848	USD	89
2014-11-01 to 2015-04-30	-114,150	USD	181
2014-02-01 to 2014-04-30	-116,446	USD	89
2013-11-01 to 2014-04-30	-164,903	USD	181

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-02-01 to 2015-04-30	17,920	USD	89
2014-11-01 to 2015-04-30	37,426	USD	181
2014-02-01 to 2014-04-30	19,080	USD	89
2013-11-01 to 2014-04-30	32,843	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-04-30	1,135,701	USD
At 2014-10-31	992,359	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-04-30	97,798	USD
At 2014-10-31	101,055	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-04-30	6,359,055	shares
At 2014-10-31	6,359,055	shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-04-30	85,728	USD
At 2014-10-31	62,144	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-02-01 to 2015-04-30	59,848	USD	89
2014-11-01 to 2015-04-30	114,150	USD	181
2014-02-01 to 2014-04-30	116,446	USD	89
2013-11-01 to 2014-04-30	245,559	USD	181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-11-01 to 2015-04-30	-3,257	USD	181
2013-11-01 to 2014-04-30	-17,342	USD	181

Inspect the source

Entity: SCIVANTA MEDICAL CORP / CIK 0001093285
Captured: 2026-09-23 02:43 UTC
SEC response SHA-256: 4f6048e360cbdd1634f7482633d4231e57bfeebc7b3dda369643e8034cb8f23b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001093285.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))